Premature activation of the HIV RNase H drives the virus into suicide: A novel microbicide?

AIDS Research and Human Retroviruses

Volumn 28, Issue 11, 2012, Pages 1397-1403

  Broecker, Felix ^a,b,e   Andrae, Karsten ^c   Moelling, Karin ^a,b,d  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

^c ZUSE INSTITUTE BERLIN   (Germany)

^d LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

^e FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 BENZOYL 1 [(4 METHOXY 1H PYRROLO[2,3 B]PYRIDIN 3 YL)OXOACETYL] 2 METHYLPIPERAZINE; ACIDFORM; ANTISENSE OLIGODEOXYNUCLEOTIDE; C 31 G; C 52 L; CARRAGEENAN; CELLULOSE SULFATE; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CYANOVIRIN N; DAPIVIRINE; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; LOCKED NUCLEIC ACID; MARAVIROC; MICROBICIDE; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NONOXINOL 9; PRO 2000; PSC RANTES; RIBONUCLEASE H; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; UNCLASSIFIED DRUG; VIVAGEL;

ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; BINDING SITE; DNA BINDING; DNA RNA HYBRIDIZATION; ENZYME ACTIVATION; ENZYME ACTIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMATURE VIRUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; REVIEW; RNA INTERFERENCE; SUICIDE GENE; SYSTEMATIC REVIEW; VAGINA; VIRUS GENOME; VIRUS INFECTIVITY; VIRUS PARTICLE; VIRUS REPLICATION;

ANIMALS; ANTI-INFECTIVE AGENTS; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MICE; MICE, SCID; RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS; RNA, VIRAL; VAGINA; VIRAL LOAD; VIRUS REPLICATION;

EID: 84868545761     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2012.0067     Document Type: Review

References (53)

1. Coffin JM, Hughes SH, and Varmus HE (Eds.): Retroviruses. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1997.
2. Moelling K, Bolognesi DP, Bauer H, Buesen W, and Plas-smann HW: Association of the viral reverse transcriptase with an enzyme degrading the RNA moiety of RNA-DNA hybrids. Nat New Biol 1971;234:240-243.
3. Moelling K: Reverse transcriptase and RNase H: Present in a murine virus and in both subunits of an avian virus. Cold Spring Harb Symp Quant Biol 1975;39:969-973.
4. Hansen J, Schulze T, Mellert W, and Moelling K: Identification and characterization of HIV-specific RNase H by monoclonal antibody. EMBO J 1988;7:239-243.
5. Flint SJ, American Society for Microbiology: Principles of Virology, 3rd ed. ASM Press, Washington, DC, 2009.
6. Dannull J, Surovoy A, Jung G, and Moelling K: Specific binding of HIV-1 nucleocapsid protein to PSI RNA in vitro requires N-terminal zinc finger and flanking basic amino acid residues. EMBO J 1994;13:1525-1533.
7. Mougel M, Cimarelli A, and Darlix JL: Implications of the nucleocapsid and the microenvironment in retroviral reverse transcription. Viruses 2010;2:939-960.
8. Levin JG, Mitra M, Mascarenhas A, and Musier-Forsyth K: Role of HIV-1 nucleocapsid protein in HIV-1 reverse transcription. RNA Biol 2010;7:754-774.
9. Wohrl BM and Moelling K: Interaction of HIV-1 ribonucle-ase H with polypurine tract containing RNA-DNA hybrids. Biochemistry 1990;29:10141-10147.
10. Sarafianos SG, Das K, Tantillo C, et al.: Crystal structure of HIV-1 reverse transcriptase in complex with a polypurine tract RNA:DNA. EMBO J 2001;20:1449-1461.
11. Volkmann S, Jendis J, Frauendorf A, and Moelling K: Inhibition of HIV-1 reverse transcription by triple-helix forming oligonucleotides with viral RNA. Nucleic Acids Res 1995;23:1204-1212.
12. Wohrl BM, Volkmann S, and Moelling K: Mutations of a conserved residue within HIV-1 ribonuclease H affect its exo-and endonuclease activities. J Mol Biol 1991;220:801-818.
13. Malik HS and Eickbush TH: Phylogenetic analysis of ribo-nuclease H domains suggests a late, chimeric origin of LTR retrotransposable elements and retroviruses. Genome Res 2001;11:1187-1197.
14. Ma BG, Chen L, Ji HF, Chen ZH, Yang FR, Wang L, Qu G, Jiang YY, Ji C, and Zhang HY: Characters of very ancient proteins. Biochem Biophys Res Commun 2008;366:607-611.
15. Champoux JJ and Schultz SJ: Ribonuclease H: Properties, substrate specificity and roles in retroviral reverse transcription. FEBS J 2009;276:1506-1516.
16. Nowotny M: Retroviral integrase superfamily: The structural perspective. EMBO Rep 2009;10:144-151.
17. Song JJ, Smith SK, Hannon GJ, and Joshua-Tor L: Crystal structure of Argonaute and its implications for RISC slicer activity. Science 2004;305:1434-1437.
18. Moelling K, Matskevich A, and Jung JS: Relationship between retroviral replication and RNA interference machineries. Cold Spring Harb Symp Quant Biol 2006;71:365-368.
19. Cerritelli SM and Crouch RJ: Ribonuclease H: The enzymes in eukaryotes. FEBS J 2009;276:1494-1505.
20. Cerritelli SM, Frolova EG, Feng C, Grinberg A, Love PE, and Crouch RJ: Failure to produce mitochondrial DNA results in embryonic lethality in Rnaseh1 null mice. Mol Cell 2003; 11:807-815.
21. Kwok T, Heinrich J, Jung-Shiu J, Meier MG, Mathur S, and Moelling K: Reduction of gene expression by a hairpin-loop structured oligodeoxynucleotide: Alternative to siRNA and antisense. Biochim Biophys Acta 2009;1790:1170-1178.
22. Crow YJ, Leitch A, Hayward BE, et al.: Mutations in genes encoding ribonuclease H2 subunits cause Aicardi-Goutieres syndrome and mimic congenital viral brain infection. Nat Genet 2006;38:910-916.
23. Kochiwa H, Tomita M, and Kanai A: Evolution of ribonu-clease H genes in prokaryotes to avoid inheritance of redundant genes. BMC Evol Biol 2007;7:128.
24. Tisdale M, Schulze T, Larder BA, and Moelling K: Mutations within the RNase H domain of HIV-1 reverse transcriptase abolish virus infectivity. J Gen Virol 1991;72:59-66.
25. Volkmann S, Wohrl BM, Tisdale M, and Moelling K: Enzymatic analysis of two HIV-1 reverse transcriptase mutants with mutations in carboxyl-terminal amino acid residues conserved among retroviral ribonucleases H. J Biol Chem 1993;268:2674-2683.
26. Moelling K, Abels S, Jendis J, Matskevich A, and Heinrich J: Silencing of HIV by hairpin-loop-structured DNA oligonu-cleotide. FEBS Lett 2006;580:3545-3550.
27. Matskevich AA, Ziogas A, Heinrich J, Quast SA, and Moelling K: Short partially double-stranded oligodeox-ynucleotide induces reverse transcriptase/RNase H-mediated cleavage of HIV RNA and contributes to abrogation of infectivity of virions. AIDS Res Hum Retroviruses 2006;22:1220-1230.
28. Karim SS and Karim QA: Antiretroviral prophylaxis for HIV prevention reaches a key milestone. Lancet 2012;379:2047-2048.
29. Jennings R and Clegg A: The inhibitory effect of spermicidal agents on replication of HSV-2 and HIV-1 in vitro. J Anti-microb Chemother 1993;32:71-82.
30. Moench TR, Whaley KJ, Mandrell TD, Bishop BD, Witt CJ, and Cone RA: The cat/feline immunodeficiency virus model for transmucosal transmission of AIDS: Nonoxynol-9 contraceptive jelly blocks transmission by an infected cell inoculum. AIDS 1993;7:797-802.
31. Van Damme L, Ramjee G, Alary M, et al.: Effectiveness of COL-1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: A randomised controlled trial. Lancet 2002;360:971-977.
32. Peterson L, Nanda K, Opoku BK, et al.: SAVVY (C31G) gel for prevention of HIV infection in women: A Phase 3, double-blind, randomized, placebo-controlled trial in Ghana. PLoS One 2007;2:e1312.
33. Feldblum PJ, Adeiga A, Wevill S, et al.: SAVVY vaginal gel (C31G) for prevention of HIV infection: A randomized controlled Trial in Nigeria. PLoS One 2008;3:e1474.
34. McCormack S, Ramjee G, Kamali A, et al.: PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): A phase 3, randomised, doubleblind, parallel group trial. Lancet 2010;376:1329-1337.
35. Skoler-Karpoff S, Ramjee G, Ahmed K, et al.: Efficacy of Carraguard for prevention of HIV infection in women in South Africa: A randomised, double-blind, placebo-controlled trial. Lancet 2008;372:1977-1987.
36. Van Damme L, Govinden R, Mirembe FM, et al.: Lack of effectiveness of cellulose sulphate gel for the prevention of vaginal HIV transmission. N Engl J Med 2008;359:463-472.
37. O'Loughlin J, Millwood IY, McDonald HM, Price CF, Kaldor JM, and Paull JR: Safety, tolerability, and pharmacokinetics of SPL7013 gel (VivaGel): A dose ranging, phase I study. Sex Transm Dis 2010;37:100-104.
38. Abdool Karim SS, Richardson BA, Ramjee G, et al.: Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women. AIDS 2011;25:957-966.
39. von Mollendorf CE, Van Damme L, and Moyes JA: Results of a safety and feasibility study of the diaphragm used with ACIDFORM Gel or K-Y Jelly. Contraception 2010;81:232-239.
40. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al.: Effectiveness and safety of tenofovir gel, an antiretroviral mi-crobicide, for the prevention of HIV infection in women. Science 2010;329:1168-1174.
41. Patton DL, Sweeney YT, Balkus JE, et al.: Preclinical safety assessments of UC781 anti-human immunodeficiency virus topical microbicide formulations. Antimicrob Agents Che-mother 2007;51:1608-1615.
42. Nel AM, Coplan P, Smythe SC, et al.: Pharmacokinetic assessment of dapivirine vaginal microbicide gel in healthy, HIV-negative women. AIDS Res Hum Retroviruses 2010;26:1181-1190.
43. Tsai CC, Emau P, Jiang Y, et al.: Cyanovirin-N gel as a topical microbicide prevents rectal transmission of SHIV89.6P in macaques. AIDS Res Hum Retroviruses 2003;19:535-541.
44. Veazey RS, Klasse PJ, Schader SM, et al.: Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion. Nature 2005;438:99-102.
45. Lederman MM, Veazey RS, Offord R, et al.: Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 2004;306:485-487.
46. Veazey RS, Ketas TJ, Dufour J, et al.: Protection of rhesus macaques from vaginal infection by vaginally delivered maraviroc, an inhibitor of HIV-1 entry via the CCR5 co-receptor. J Infect Dis 2010;202:739-744.
47. Neff CP, Kurisu T, Ndolo T, Fox K, and Akkina R: A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice. PLoS One 2011;6:e20209.
48. Moelling K: Targeting the retroviral RNase H by rational drug design. AIDS 2012 [Epub ahead of print];DOI:10.1097/QAD.0b013e32835537d3.
49. Heinrich J, Mathur S, Matskevich AA, and Moelling K: Oligonucleotide- mediated retroviral RNase H activation leads to reduced HIV-1 titer in patient-derived plasma. AIDS 2009;23:213-221.
50. Matzen K, Elzaouk L, Matskevich AA, Nitzsche A, Heinrich J, and Moelling K: RNase H-mediated retrovirus destruction in vivo triggered by oligodeoxynucleotides. Nat Biotechnol 2007;25:669-674.
51. Heinrich J, Schols D, and Moelling K: A short hairpin loop-structured oligodeoxynucleotide targeting the virion-associated RNase H of HIV inhibits HIV production in cell culture and in huPBL-SCID mice. Intervirology 2012;55:242-246.
52. Wittmer-Elzaouk L, Jung-Shiu J, Heinrich J, and Moelling K: Retroviral self-inactivation in the mouse vagina induced by short DNA. Antiviral Res 2009;82:22-28.
53. Moschos SA, Frick M, Taylor B, et al.: Uptake, efficacy, and systemic distribution of naked, inhaled short interfering RNA (siRNA) and locked nucleic acid (LNA) antisense. Mol Ther 2011;19:2163-2168.